Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

60
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
60
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

939
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
939
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.3K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.3K
Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

897
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
897

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling trends: insights into medicines reimbursement recommendations and health technology management in Ireland (2018-2023).

International journal of technology assessment in health care·2026
Same author

An Atypical Case of Toxic Epidermal Necrolysis Associated With Ceftriaxone.

Cureus·2025
Same author

Probability of vertical HIV transmission: a systematic review and meta-regression.

The lancet. HIV·2025
Same author

A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2025
Same author

Utilization and expenditure on medicines for the management of osteoporosis in Ireland: A repeated cross-sectional study.

British journal of clinical pharmacology·2025
Same author

DCLK1-mediated regulation of invadopodia dynamics and matrix metalloproteinase trafficking drives invasive progression in head and neck squamous cell carcinoma.

Molecular cancer·2025

Related Experiment Video

Updated: Mar 17, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

The Pharmacoeconomic Evaluation Process in Ireland.

Laura McCullagh1,2, Michael Barry3,4

  • 1Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, Trinity College Dublin, St James's University Teaching Hospital, Dublin 8, Ireland. mcculllm@tcd.ie.

Pharmacoeconomics
|July 31, 2016
PubMed
Summary

In Ireland, the National Centre for Pharmacoeconomics (NCPE) evaluated 230 drugs for reimbursement. Most drugs received positive recommendations, often after price negotiations, highlighting the pharmacoeconomic evaluation process efficiency.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.0K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K

Related Experiment Videos

Last Updated: Mar 17, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.0K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

9.3K

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Drug Reimbursement

Background:

  • Ireland mandates formal pharmacoeconomic evaluations (PE) for new drug reimbursement decisions.
  • The National Centre for Pharmacoeconomics (NCPE) conducts all drug evaluations in Ireland.

Purpose of the Study:

  • To describe the drug evaluation process in Ireland.
  • To examine the progression of drugs through the NCPE's evaluation system.

Main Methods:

  • Investigated the movement of all drugs submitted to the NCPE between January 2010 and December 2015.
  • Analyzed 230 Rapid Review submissions to determine the need for full pharmacoeconomic evaluations.

Main Results:

  • Out of 230 submissions, 108 (47%) did not require a full PE, with 100 receiving positive reimbursement recommendations (25 with price reductions, 35 with usage restrictions).
  • 122 submissions (53%) required a full PE; 12 proceeded to reimbursement after price negotiations, 24 failed to establish cost-effectiveness, and 15 are ongoing.
  • Of 71 completed full PEs, 19 were recommended for reimbursement, 8 were not, and 44 were not recommended at the submitted price, with 34 subsequently approved after price negotiations.

Conclusions:

  • The NCPE evaluated 230 drugs, with 165 (72%) receiving positive reimbursement recommendations.
  • Price reductions were advised in 43% of positively recommended cases, and usage restrictions in 21%.
  • The pharmacoeconomic evaluation process, including price negotiations, facilitates drug reimbursement in Ireland.